Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Net Income towards Common Stockholders (2020 - 2023)

Historic Net Income towards Common Stockholders for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.1 million.

  • Terns Pharmaceuticals' Net Income towards Common Stockholders fell 3127.45% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 4900.8%. This contributed to the annual value of -$89.6 million for FY2024, which is 78.76% up from last year.
  • Terns Pharmaceuticals' Net Income towards Common Stockholders amounted to -$21.1 million in Q4 2023, which was down 3127.45% from -$29.8 million recorded in Q3 2023.
  • Over the past 5 years, Terns Pharmaceuticals' Net Income towards Common Stockholders peaked at -$9.2 million during Q1 2020, and registered a low of -$29.8 million during Q3 2023.
  • Its 4-year average for Net Income towards Common Stockholders is -$15.2 million, with a median of -$13.9 million in 2022.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 210.51% in 2021, then plummeted by 7697.38% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$11.1 million in 2020, then dropped by 29.0% to -$14.3 million in 2021, then fell by 12.07% to -$16.1 million in 2022, then plummeted by 31.27% to -$21.1 million in 2023.
  • Its Net Income towards Common Stockholders stands at -$21.1 million for Q4 2023, versus -$29.8 million for Q3 2023 and -$17.9 million for Q2 2023.